Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study [Hematologic Malignancy]

Conclusion
Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.

Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Lesokhin, Ansell, Armand, Scott, Halwani, Gutierrez, Millenson, Cohen, Schuster, Lebovic, Dhodapkar, Avigan, Chapuy, Ligon, Freeman, Rodig, Cattry, Zhu, Grosso, Bradley Garelik, Shipp, Borrello, Timmerman Tags: Non-Hodgkin's Lymphoma Hematologic Malignancy Source Type: research